文献速递系统性红斑狼疮

组蛋白去乙酰化酶抑制剂靶向系统性红斑狼疮I型干扰素与B细胞异常

Identification of Histone Deacetylase Inhibitor Targeting Type I Interferon and B Cell Abnormalities in Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Rheumatol · 2026-02-17

本研究从化学库中筛选出可同时抑制I型干扰素(IFN-I)产生和自身抗体生成的药物,发现临床已批准的泛HDAC抑制剂伏立诺他(vorinostat)可抑制IFN-I产生及浆细胞分化。伏立诺他通过抑制TBK1磷酸化和IRF3核转位减少IFN-I,并通过抑制浆细胞关键转录因子表达阻断浆细胞分化;抑制HDAC6可抑制IFN-I诱导和浆细胞分化。在SLE倾向小鼠中,伏立诺他减轻肺炎症、改善死亡率及肾脏疾病严重程度。

要点

  • 伏立诺他同时抑制IFN-I产生和浆细胞分化。
  • 伏立诺他通过抑制TBK1磷酸化及IRF3核转位减少IFN-I。
  • 抑制HDAC6可抑制IFN-I诱导和浆细胞分化。

核心结论

  • 伏立诺他通过靶向HDAC6同时抑制IFN-I产生和浆细胞分化,减轻SLE倾向小鼠疾病严重程度。

研究设计与样本

  • 从化学库中鉴定IFN-I产生抑制剂,并检测其抑制IFN-I上游信号分子表达与磷酸化及B细胞向浆细胞分化的效果与机制。
  • 在SLE倾向小鼠中检测该抑制剂是否减轻疾病严重程度。

主要发现

  • 伏立诺他抑制IFN-I产生和浆细胞分化。
  • 伏立诺他通过抑制TBK1磷酸化和后续IRF3核转位抑制IFN-I产生。
  • 伏立诺他通过抑制浆细胞必需转录因子的表达抑制浆细胞分化。
  • 抑制HDAC6可抑制IFN-I诱导和浆细胞分化。
  • 伏立诺他通过降低IFN-I改善STING相关婴儿期起病血管病小鼠的肺部炎症,并通过抑制IFN-I诱导和B细胞分化减轻NZB/W F1小鼠的死亡率和肾脏疾病严重程度。

临床怎么用

  • 伏立诺他是SLE的有前景治疗药物,可能使需要更有效且耐受性更好治疗的SLE患者获益。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Systemic lupus erythematosus (SLE) is characterized by increased Type I interferon (IFN-I) and autoantibody production. This study aimed to identify drugs that can inhibit both IFN-I and autoantibody production. METHODS: We identified an inhibitor of IFN-I production from a chemical library. Subsequently, we examined its efficacy and underlying mechanisms in suppressing the expression and phosphorylation of upstream signaling molecules for IFN-I production and the differentiation of B cells into plasma cells. Additionally, we examined whether it could alleviate disease severity in SLE-prone mice. RESULTS: We showed that vorinostat, a clinically approved pan-histone deacetylase (HDAC) inhibitor, inhibited both IFN-I production and plasma cell differentiation. Vorinostat suppressed IFN-I production by inhibiting TBK1 phosphorylation and the subsequent IRF3 nuclear translocation and suppressed plasma cell differentiation by inhibiting the expression of essential transcriptional factors for plasma cells. Notably, inhibiting HDAC6 suppressed IFN-I induction and plasma cell differentiation. Furthermore, vorinostat ameliorated lung inflammation in STING-associated vasculopathy with onset in infancy mice by decreasing IFN-I and alleviated the mortality and severity of renal disease in New Zealand Black/White F1 mice by suppressing IFN-I induction and B cell differentiation. CONCLUSION: Vorinostat ameliorates the severity of disease in SLE-prone mice by simultaneously suppressing IFN-I production and plasma cell differentiation by targeting HDAC6. Thus, vorinostat is a promising therapeutic agent for SLE and may benefit patients with SLE requiring more effective and better-tolerated therapies.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Hirayama T, Konaka H, Kato Y, et al. Identification of Histone Deacetylase Inhibitor Targeting Type I Interferon and B Cell Abnormalities in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2026. PMID: 41235819. doi:10.1002/art.43434

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。